What is Nabla Bio?
Headquartered in Cambridge, Massachusetts, Nabla Bio operates at the intersection of machine learning and molecular biology. The company specializes in the development of an AI-native platform designed to engineer high-affinity, developable protein therapeutics. By addressing the inherent challenges of protein design—such as stability, specificity, and manufacturability—Nabla Bio provides a critical infrastructure layer for modern drug discovery. Its market position is defined by its ability to solve complex biological problems that have historically hindered traditional pharmaceutical development, making it a high-value partner for organizations seeking to accelerate their pipeline of novel biologics.
How much funding has Nabla Bio raised?
Nabla Bio has raised a total of $37M across 2 funding rounds:
Angel/Seed
$11M
Series A
$26M
Angel/Seed (2021): $11M with participation from Cantos Ventures, Fifty Years, Zetta Venture Partners, and Khosla Ventures
Series A (2024): $26M led by Bristol-Myers Squibb, Takeda, AstraZeneca, and Radical Ventures
Key Investors in Nabla Bio
Khosla Ventures
A prominent venture capital firm founded by Vinod Khosla, specializing in providing strategic assistance and capital to breakthrough technologies across AI, health, and sustainable energy sectors.
Bristol-Myers Squibb
A global biopharmaceutical leader focused on discovering and developing innovative medications for serious diseases, including oncology, cardiovascular, and immunoscience.
Takeda
A research-driven global pharmaceutical company with a long history of developing therapies in gastroenterology, oncology, neuroscience, and rare diseases.
What's next for Nabla Bio?
With the recent capital infusion, Nabla Bio is well-positioned to expand its internal therapeutic pipeline and deepen its strategic alliances with major biopharmaceutical entities. The focus will likely shift toward scaling its computational infrastructure and increasing the throughput of its wet-lab validation capabilities. As the company matures, the integration of its AI-driven insights into clinical-stage programs will be the primary driver of long-term value creation. Investors are closely monitoring how the firm utilizes this financing to navigate the complexities of drug development, particularly in high-need therapeutic areas where precision protein engineering can offer superior clinical outcomes compared to conventional modalities.
See full Nabla Bio company page
